Prefrontal cortex lesions and scopolamine impair attention performance of C57BL/6 mice in a novel 2-choice visual discrimination task.
Sustained attention is defined as the ability or capacity to remain focused on the occurrence of rare events over long periods of time. We describe here the development of a novel, operant-based attention task that can be learned by mice in 8-10 days. Mice were trained on a 2-choice visual discrimination task in an operant chamber, wherein the correct response on any given trial was a lever-press cued by a stimulus light. Upon reaching a criterion of greater than 80% correct responses, all subjects were tested in a mixed-trial attention paradigm combining four different stimulus durations within a single session (0.5, 1, 2, or 10 s). During attention testing, the percentage of correct responses decreased as a function of stimulus duration, indicating a performance decrement which parallels increasing attentional demand within the task. Pretreatment with the muscarinic-receptor antagonist scopolamine yielded a reliable, dose-dependent performance deficit whereas nicotine treatment improved the percentage of correct responses during trials with the greatest attentional demand. Moreover, medial prefrontal cortex lesions impaired attention performance without affecting acquisition or retention of the discrimination rule. These results underscore the utility of this task as a novel means of assessing attentional processes in mice in a relatively high-throughput manner.
Merck Research Laboratories, CNS Pharmacology, 33 Avenue Louis Pasteur, Boston, MA 02115, USA.
Gregory M
GM
Dillon
Delia
D
Shelton
A P
AP
McKinney
Michael
M
Caniga
Jacob N
JN
Marcus
Mitchell T
MT
Ferguson
Thomas J
TJ
Kornecook
Jean-Cosme
JC
Dodart
D000818:Animals; D001288:Attention / Q000187:drug effects / Q000502:physiology*; D003216:Conditioning, Operant / Q000502:physiology; D004192:Discrimination, Psychological / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D007858:Learning / Q000502:physiology; D008297:Male; D008568:Memory / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009538:Nicotine / Q000494:pharmacology; D018722:Nicotinic Agonists / Q000494:pharmacology; D010775:Photic Stimulation; D017397:Prefrontal Cortex / Q000187:drug effects / Q000502:physiology*; D011976:Receptors, Muscarinic / Q000378:metabolism*; D012601:Scopolamine / Q000494:pharmacology; D013997:Time Factors; D014796:Visual Perception / Q000187:drug effects / Q000502:physiology
D018727:Muscarinic Antagonists; D018722:Nicotinic Agonists; D011976:Receptors, Muscarinic; D009538:Nicotine; D012601:Scopolamine